EvolveImmune Therapeutics is developing next-generation T cell engagers to address immunologically “cold” solid tumors. Its EVOLVE™ platform uniquely integrates co-stimulatory domains into TCEs, enabling more robust anti-tumor responses. Lead candidate EVT-201 is in early clinical development, with a combination trial launching in mid-2025.